Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 9/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25906851 | 0.83 | F7 (0.38) | METAP1PGRSRD5A1SRD5A2S100A4 | |
| SCHEMBL31164686 | 0.80 | HTT (0.44) | METAP1HTTPGRSRD5A1SRD5A2 | |
| SCHEMBL21694411 | 0.78 | METAP1 (0.41) | METAP1HTTSRD5A1HTR2AHTR2C | |
| SCHEMBL29427206 | 0.78 | METAP1 (0.41) | METAP1HTTSRD5A1HTR2AHTR2C | |
| SCHEMBL2963487 | 0.75 | METAP1 (0.39) | METAP1PGRSRD5A1SRD5A2S100A4 | |
| SCHEMBL19957253 | 0.72 | CD44 (0.38) | CYP3A4LMNA | |
| SCHEMBL29248715 | 0.72 | MPO (0.47) | METAP1CYP3A4 | |
| SCHEMBL3870099 | 0.71 | METAP1 (0.36) | METAP1HTTSRD5A1SRD5A2S100A4 | |
| SCHEMBL6826934 | 0.69 | KDM4E (0.46) | SRD5A1SRD5A2HTR2CHTR2BLMNA | |
| SCHEMBL308273 | 0.69 | HTR6 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-3058941-B1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2019-05-22 | — | — | EP | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3058941-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | Boston Biomedical, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2194987-B1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2016-05-18 | — | — | EP | disclosed |
| CN-103153975-B | Novel naphthoquinones for use in the treatment of disease | Hangzhou Yier Biological Technology Co.,Ltd. (CN) | 2016-01-20 | — | — | CN | disclosed |
| US-8877803-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8871802-B2 | Naphthoquinones for disease therapies | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2014-10-28 | — | — | US | disclosed |
| CN-103288787-A | Novel STAT3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL INC | 2013-09-11 | — | — | CN | disclosed |
| US-20130150437-A1 | NAPHTHOQUINONES FOR DISEASE THERAPIES | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2013-06-13 | — | — | US | disclosed |
| CN-103153975-A | Novel naphthoquinones for use in the treatment of disease | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO LTD | 2013-06-12 | — | — | CN | disclosed |
| CN-101854937-B | Novel stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL INC | 2013-03-27 | — | — | CN | disclosed |
| WO-2012024818-A1 | NOVEL ANPHTHOQUINONES FOR DISEASE THERAPIES | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2012-03-01 | — | — | WO | disclosed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| CN-101854937-A | Novel stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL INC | 2010-10-06 | — | — | CN | disclosed |
| EP-2194987-A2 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | Boston Biomedical, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009036059-A2 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | METAP1 3024/4885HTT 3582/4885PGR 2658/4885 |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, JAK2 | METAP1 3097/4885HTT 3688/4885PGR 2621/4885 |
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | STAT3, STAT1, JAK2 | METAP1 2922/4885HTT 3729/4885PGR 2614/4885 |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | METAP1 3024/4885HTT 3582/4885PGR 2658/4885 |
| US-20130150437-A1 | NAPHTHOQUINONES FOR DISEASE THERAPIES | NQO1, NME2, CYP27B1 | METAP1 4105/4885HTT 626/4885PGR 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.